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Abstract: Tremendous developments in the field of biomedical imaging in the past two decades have resulted in the transformation of 
anatomical imaging to molecular-specific imaging. The main approaches towards imaging at a molecular level are the development of 
high resolution imaging modalities with high penetration depths and increased sensitivity, and the development of molecular probes with 
high specificity. The development of novel molecular contrast agents and their success in molecular optical imaging modalities have lead 
to the emergence of molecular optical imaging as a more versatile and capable technique for providing morphological, spatial, and 
functional information at the molecular level with high sensitivity and precision, compared to other imaging modalities. In this review, 
we discuss a new class of dynamic contrast agents called magnetomotive molecular nanoprobes for molecular-specific imaging. 
Magnetomotive agents are superparamagnetic nanoparticles, typically iron-oxide, that are physically displaced by the application of a 
small modulating external magnetic field. Dynamic phase-sensitive position measurements are performed using any high resolution 
imaging modality, including optical coherence tomography (OCT), ultrasonography, or magnetic resonance imaging (MRI). The 
dynamics of the magnetomotive agents can be used to extract the biomechanical tissue properties in which the nanoparticles are bound, 
and the agents can be used to deliver therapy via magnetomotive displacements to modulate or disrupt cell function, or hyperthermia to 
kill cells. These agents can be targeted via conjugation to antibodies, and in vivo targeted imaging has been shown in a carcinogen-
induced rat mammary tumor model. The iron-oxide nanoparticles also exhibit negative T2 contrast in MRI, and modulations can produce 
ultrasound imaging contrast for multimodal imaging applications.  
Keywords: Magnetomotion, molecular imaging, optical coherence tomography, hyperthermia, superparamagnetic iron oxide nanoparticles, 
targeting. 
1. INTRODUCTION 
Molecular imaging in living organisms including humans is 
aimed at the visualization, characterization and measurement of 
biological processes at a cellular level or molecular level using in 
vivo methods. Spectacular advances in the field of biomedical 
imaging in the past two decades have resulted in the transformation 
of anatomical imaging to molecular-specific imaging. The 
developments in chemistry, nanotechnology, biotechnology, and 
engineering have had a profound impact on the biomedical imaging 
research community, allowing scientists to identify, follow, and 
quantify subcellular biological processes and pathways within a 
living organism. The recent developments in nano-sized particles 
and devices that can be conjugated with several functional 
molecules including tumor-specific ligands, antibodies, anticancer 
drugs, and fluorescent imaging probes have revolutionized the 
arena of cancer therapeutics and diagnostic imaging. Knowing the 
relationship between the occurrence of various molecular targets to 
diseases like cancer, and the deliverable concentrations of targeted 
agents, monitoring these targets through molecular imaging would 
play an important role in oncology, for example, by aiding the early 
detection of malignancies, locating metastatic disease, staging 
tumors, evaluating the availability of therapeutic targets, and 
monitoring the efficacy of treatment. 
The goal of biomedical imaging is to provide structural and 
functional information, and to visualize biological processes in 
vivo, from the nanoscale to the molecular, cellular, and systems 
scale, noninvasively. Development of high resolution imaging 
modalities with high penetration depths and increased sensitivity 
has been one major stream of research towards imaging at a 
molecular level. The current field of biomedical imaging comprises 
a multitude of tools like magnetic resonance imaging (MRI), x-ray 
computed tomography (CT), ultrasonography (US), positron 
emission tomography (PET), and single photon emission computed  
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tomography (SPECT) that have developed over the last century, 
while optical technologies including optical coherence tomography 
(OCT) and microscopy, multiphoton microscopy (MPM), and 
diffusion optical tomography are emerging as promising modalities 
for optical molecular imaging. The sensitivity and specificity of 
imaging and detection for these imaging modalities can be 
enhanced by the introduction of a molecular probe, although 
ongoing research efforts have also been directed at sensing intrinsic 
optical molecular signatures.  
The optical imaging modalities have unique capabilities to 
distinguish cells and tissues based on their optical scattering and 
absorption properties. Most of the optical imaging techniques rely 
on the absorption and scattering changes of light as it traverses 
biological tissue, providing optical signal changes that carry 
information about the tissues. Biological samples are fairly 
transparent in the near-infrared (NIR) window of the 
electromagnetic spectrum [650-1350 nm], which is often termed as 
the biological window, making this spectral region ideal for optical 
imaging applications. The contrast generated could be either from 
the endogenous signals from specific molecules or from targeted 
agents attached to specific molecules. The development of novel 
molecular contrast agents and their success in molecular optical 
imaging modalities have led to the emergence of molecular optical 
imaging as a more versatile and capable technique for providing 
morphological, spatial, and functional information at the molecular 
level with high sensitivity and precision, compared to other imaging 
modalities. This review article will provide a brief overview of the 
development of a new class of dynamic contrast agents called 
magnetomotive molecular nanoprobes, will discuss their in vivo 
applications in optical molecular imaging, and will address the 
challenges and future directions on how to improve the state-of-the-
art cancer diagnostics and therapy using these novel contrast agents 
and mechanisms.  
2. MOLECULAR NANOPROBES 
The recent developments in nanotechnology have contributed 
enormously to the field of nanomedicine, resulting in a wide variety 
of novel agents with sizes ranging from 5-200 nanometers for 
applications in bioimaging, biosensing and therapy. A wide variety 
of nanostructures including nanoparticles [1-4], nanospheres [5,6], 
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nanoshells [7-13], nanorods [14-20], nanocages [20-23], nanotubes 
[23-27], nanostars [28], nanowires [29, 30] and quantum dots [31-
35] have been fabricated using materials that are optically or 
chemically active. Each exhibit some optical property that can be 
exploited by existing imaging modalities to achieve additional 
contrast information. Nanoparticles made of materials like gold, 
silver, iron oxide, gadolinium, carbon, and a wide variety of 
polymers, have been used as optical contrast agents with different 
optical imaging modalities. In addition to their primary aim of 
generating molecular-specific contrast, these nanoparticle agents 
can be functionalized to target specific sites, enabling applications 
such as site-specific delivery of drugs [36-41], nucleotides, proteins 
or genetic materials, and hyperthermia [40, 42, 43].  
A number of factors determine the clinical usefulness of 
nanoparticles. Their physical and functional biokinetic properties, 
clearance profiles, biodistribution, biocompatibility, and long-term 
toxicity need to be carefully considered for their potential use in in 
vivo applications. Nanoparticles having sizes smaller than 50 nm 
show prolonged blood half-life times compared to larger ones. 
Larger particles are quickly uptaken by phagocytic cells. 
Expectedly, particles with longer circulation times have a greater 
probability of reaching the target sites. Hydrophilic particles have a 
longer blood half-life compared to hydrophobic particles. Particles 
that are hydrophilic in nature with no charge on them, or have very 
low negative charges, are known to have longer blood half-life 
times. Generally, nanoparticles used for biomedical applications are 
coated with different surfactants and agents to prevent 
agglomeration, improve their dispersibility and biocompatibility in 
physiological media, reduce toxicity, and alter pharmacokinetics 
and biodistribution [36]. The conjugation with various functional 
groups and targeting ligands also is aided by choosing a desirable 
surface coating.  
2.1. Superparamagnetic Iron Oxide Magnetic Nanoparticles 
(SPIONs)  
The use of iron oxide for in vitro diagnostic applications has 
been in practice for over 40 years [44]. Superparamagnetic iron 
oxide magnetic nanoparticles (SPIONs) have a very promising role 
as ultra-sensitive molecular-specific imaging nanoprobes. 
Magnetitie (Fe3O4), which is a common form of iron oxide, has 
preferred qualities such as high magnetization values, high specific 
heat absorption rates (for hyperthermia), and well-known 
biocompatibility for in vivo applications. Iron oxide nanoparticles, 
due to their small sizes and extremely large relative surface area, 
exhibit superparamagnetic phenomena and find numerous 
applications in the field of biomedical imaging. Their unique 
paramagnetic properties with strong T2 and negative T2* contrast 
have made them attractive contrast agents in MRI [45].  
SPIONs can be synthesized through different methods, the 
simplest one being a coprecipitation method where a mixture of 
ferrous and ferric ion salts in alkaline medium and an oxygen-free 
environment yield iron oxide nanoparticles of sizes from 20 to 90 
nm [36, 46-49]. The coprecipitation is usually carried out in the 
presence of materials like dextran and other polyols that form an 
outer coating over the nanoparticles. The size of particles depends 
on the ratio of the ions, types of salts, pH, and ionic strengths of the 
solutions. The main drawback of this technique, however, is the 
lack of precise control over nanoparticle size. Other techniques like 
microemulsion techniques [50, 51] and thermal decomposition 
methods [52] provide better control over the size distributions of 
the synthesized particles. Different methods of preparation of iron 
oxide nanoparticles including variations of the above 
coprecipitation technique have been discussed in detail by Gupta 
and Gupta [47]. Both inorganic metal and metal oxides, and organic 
polymers and monomers, have been used to coat iron oxide 
nanoparticles. Iron oxide nanoparticles coated with materials like 
dextran, or dextran derivatives [53, 54], albumin [54], polyethylene 
glycols (PEGs) [45, 55], and polyvinylpyrrolidone [56], have been 
reported to have high biocompatibility for in vivo applications. 
Numerous works have been reported over the past two decades on 
functionalizing iron oxide nanoparticles with a number of targeting 
agents like proteins [36, 57, 58], antibodies [46, 59-61], 
polypeptides [40, 62, 63], and oligonucleotides [64, 65]. The ease 
of their fabrication with tailored surface chemistry, 
biocompatibility, and bioconjugation possibilities have made them 
attractive choices for use in different imaging modalities and 
biomedical applications.  
2.2. Targeted Magnetic Nanoprobes 
SPIONs can be localized primarily through two mechanisms, 
active and passive targeting. The traditional approach for 
nanoparticle-based therapy is aimed at the passive targeting of 
nanoparticles to specific sites such as in tumors by exploiting the 
enhanced permeability and retention (EPR) effect associated with 
the leaky vasculature [66], thereby allowing nanoparticles to readily 
extravasate and accumulate in the tumors. The lack of lymphatic 
drainage in these inflamed tissues also aids accumulation of 
nanoagents. This would enable imaging of these malignant sites and 
delivery of therapeutic drugs. However, experiments have shown 
that nanoparticles most likely undergo opsonization in blood, 
resulting in their fast uptake by the reticulo-endothelial system 
(RES), and their final clearance from the circulation. Intravenous 
injections of SPIONs have been shown to accumulate mostly in the 
RES of the liver and spleen. As a result, a relatively low 
concentration of nanoparticles at targeting sites has become a major 
obstacle in using them for tumor imaging or therapy. Surface 
modifications, such as coating nanoparticles with polymers like 
PEG-THIOL, have proven useful to protect the nanoparticles from 
being captured by the RES, thus increasing their blood half-lives. 
Active targeting of SPIONs with target-specific ligands is 
another way to promote selective binding to biomarkers for target-
specific accumulation. Knowledge of expression profiles of various 
biomarkers in different pathological conditions will allow the 
physician to identify abnormalities at an earlier stage, monitor 
disease progression, and efficacy of treatment. The ability to 
functionalize the surface of these nanoprobes allows cell or tissue-
specific targeting. Along with the synthesis of these nanoprobes, the 
chemistry of bioconjugation has also contributed significantly to the 
development of targeted probes that can be conjugated to different 
biomarkers, proteins, peptides, or oligonucleotides. Development of 
functionalized nanoprobes for in vivo targeting is extremely 
challenging and involves multidisciplinary skills. Efficient ways to 
direct these nanoparticles to organs, tissues, tumors, and malignant 
cells have been reported by conjugating the nanoparticles with 
enzymes, proteins, antibodies, nucleotides, or peptide ligands. 
Various biomarkers and oncoproteins like HER2 [46, 60, 61, 67, 
68], or MMPs [69-71] that are known to be over-expressed at the 
sites of malignancy have been targeted using different conjugation 
techniques. The conjugating procedures depend on the nature of the 
nanoparticle coating and the conjugating ligand or proteins. 
Targeted molecular imaging using functionalized nanoprobes 
targeted to the HER2 antigen has been demonstrated on two cell 
lines with different HER2 expression levels [72] (Fig. 1). The Fc-
directed conjugation of antibodies to iron oxide magnetic 
nanoparticles (MNPs) aids their efficient immunospecific targeting 
through the free Fab portions. Multifunctionality is one of the most 
desirable qualities of these targeted nanoprobes, giving rise to 
diagnostic and therapeutic agents that can simultaneously act as 
contrast agents in imaging as well as therapeutic and drug delivery 
agents, aiding the treatment, and monitoring the progress.  
Magnetic nanoparticles that act as MR contrast agents can 
provide information on the location of the probe, and can also be 
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tailored as NIR fluorescent (NIRF) imaging probes by conjugating 
cleavable Cy5.5-derivatized peptides to their surface [73]. Contrast 
enhancement by MR results from a core of superparamagnetic iron 
oxide, while the NIRF signal results from amino-CLIO. A magnetic 
nanoparticle with a surface of aminated, cross-linked dextran has 
been used to attach a variety of biological molecules, including the 
tat peptide of the HIV tat protein, transferrin, and oligonucleotides, 
and provides a convenient platform for the attachment of Cy5.5 
peptides. SPIONs tagged with transfection agents have been 
reported as intracellular contrast agent for nuclear MRI cell 
tracking in vivo [74]. Intracellular SPIO colloid uptake in live cells 
has been quantified using cell magnetophoresis.  
2.3. Microsphere Encapsulations of Magnetic Nanoparticles 
SPIONs can be encapsulated into protein-shelled microspheres 
with sizes up to a few microns for applications involving imaging, 
targeted drug delivery, and therapy. These microspheres, due to 
their relatively large size, remain in the vasculature after 
intravenous administration, and are suitable for identifying regions 
of altered perfusion (leaky or ruptured vessels), and for targeting to 
specific markers that are over-expressed in regions of angiogenesis 
(in cancer) and atherosclerosis (in heart disease), to provide some 
examples. Protein microspheres consisting of a hydrophobic core 
composed of vegetable oil and a hydrophilic protein shell with sizes 
from 2- 5 microns have been reported as scattering contrast agents 
in OCT [75-79] (Fig. 2). These microspheres have been 
encapsulated with lipids, NIR dyes, and various nanoparticles 
including gold, carbon, melanin, and superparamagnetic iron oxide 
nanoparticles in their core and shell to effectively work as 
multimodal contrast agents in NIRF imaging, ultrasound, MRI, 
OCT, and MM-OCT [76-78]. Owing to the presence of iron oxide 
nanoparticles in their core, these microspheres can be dynamically 
modulated using an external magnetic field, thereby creating 
dynamic contrast in biological samples and additionally serving as 
dynamic probes that are discussed in the next section.  
Protein microspheres have been targeted to alpha (v) beta (3) 
integrin receptors by conjugating an RGD peptide sequence to the 
outer surface of these microspheres [76-77]. These integrin 
receptors play an important role in the development of cancer or 
angiogenesis and are also over-expressed at sites of atherosclerosis. 
RGD-functionalized microspheres have been successfully tested on 
cell lines that overexpress these integrin receptors [76, 77]. The 
possibility of controlling the in vivo rupture of microspheres to 
release its shell or core contents is another promising application of 
these agents as a means for drug administration and delivery of 
genetic material and proteins. These targeted protein microspheres 
would therefore serve as potential site-specific drug delivery 
vehicles with the capacity for relatively high payloads. 
3. APPLICATIONS  
3.1. Magnetomotion  
A wide variety of molecular specific contrast agents have been 
studied for coherence imaging applications. All previous scattering-
based probes have relied of their static scattering nature for the 
enhancement of the optical signal or to provide contrast in imaging. 
One of the main drawbacks of scattering-based probes is the 
inherent background noise that arises from the static background 
scattering of the tissues. Hence, the endogenous scattering from the 
tissue structures can be separated from the scattering caused by the 
contrast agents only through prior information about the tissue 
structure, i.e. by comparing the images before and after the 
administration of the contrast agents. Dynamic probes that can be 
modulated externally offer an elegant solution to this problem. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Molecular imaging using dextran-coated iron oxide nanoparticles functionalized with anti-HER2 antibody. (a) Schematic representation. (b) TEM. 
(c,d) Fluorescent and brightfield microscope images showing HER2 targeting using functionalized nanoparticles on SKBR-3 cells that over-express HER2 and 
HUVEC cells that have low expression of HER2. Images in (c,d) were reproduced with permission from [72]. Copyright, World Scientific Publishing Co. Pte. 
Ltd. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this paper). 
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Small perturbations in scattering can be created using dynamic 
modulation of the probes and the unperturbed background signal 
can be filtered out efficiently through post-acquisition data 
processing. Coherent imaging modalities offer high resolution and 
sensitivity at nanoscales, enabling functional imaging at the 
subcellular level, such as tracking biological processes, detecting 
flow, and sensing dynamic modulations and displacements at a 
nanoscale. In addition, the heterodyne detection capabilities can 
produce images with exceptionally high SNR. 
Magnetomotion refers to the dynamic modulation of magnetic 
agents on application of an external magnetic field. 
Magnetomotion, in general, can be rotation or translation. A 
particle with a permanent magnetic moment (strong effect) or with 
a highly anisotropic shape (weak effect) can be aligned with an 
applied magnetic field through a rotational motion [80]. Different 
properties like optical scattering cross-section, polarization-
dependent scattering, or birefringence can be modulated through 
this change in alignment due to rotation, and hence, any imaging 
modality such as OCT or PS-OCT could exploit this modulation to 
create magnetomotive contrast while imaging. An example of 
related work is the determination of antibody binding using 
birefringence measurements on alignment of magnetic 
nanoparticles [81]. Also, magnetic contrast agents whose 
fluorescence is modulated by rotation have been developed for 
microscopy [82]. In another work, a dynamic mode of optical 
contrast termed as gyromagnetic imaging [28] has been reported 
recently using gold nanostars with superparamagnetic cores. Gold 
nanostars with superparamagnetic cores are driven by a rotating 
magnetic field gradient to produce periodic variations in NIR 
scattering intensities detected in a dark-field microscope set-up. 
This periodic “twinkling” in response to a rotating magnetic field 
gradient results in a frequency-modulated signal that is converted 
into Fourier-domain images with a dramatic reduction in 
background.  
Magnetomotion of contrast agents through an externally 
modulating magnetic field is an excellent mechanism for achieving 
dynamic contrast. This can be realized by using paramagnetic 
particles as contrast agents. Human tissue exhibits an extremely 
weak magnetic susceptibility (<|10-5|). Hence the employment of 
magnetic probes with ~1 provides a large potential dynamic range 
of magnetic contrast. Iron oxide, such as magnetite, with 
paramagnetic properties and ~1 is a good candidate with known 
biocompatibility after coating with polymers such as dextran. 
Paramagnetic iron oxide MNPs have been already approved as 
contrast agents in MRI. These micron and nano-sized MNPs can be 
actuated externally using a modulating magnetic field. In the 
presence of a high magnetic field gradient, particles with high 
magnetic susceptibility embedded in tissue experience a gradient 
force, and ferromagnetic particles rotate to align their internal 
magnetization along the field. The resulting magnetomotion of the 
MNPs and the perturbation of the surrounding cells and 
extracellular matrix result in a change in the scattering properties of 
the local tissue microenvironment under observation (Fig. 3a). In an 
elastic medium, the particle returns to its original position and 
orientation after removal of the magnetic field. This permits 
modulation of its position by repetitively modulating the magnetic 
field. The resulting increase in contrast due to magnetomotion can 
be effectively detected by a coherent interferometric imaging 
technique like OCT.  
3.2. Magnetomotive Optical Coherence Tomography (MM-
OCT) 
 The ability to capture both the amplitude and phase of a 
coherent signal using interferometric techniques [83-91] has 
enabled the retrieval of additional valuable information from the 
sample. The magnetomotive response of the tissue phantom to 
different magnetic field excitations can easily be demonstrated by 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Protein microspheres as multifunctional multimodal contrast agents with flexible fabrication parameters allowing modifications of surface, shell and 
core contents. (a) Schematic representation of oil-filled protein microsphere. (b) TEM showing magnified view of the shell. (c) SEM of non-conjugated 
protein microspheres. (d) SEM of RGD poly-lysine peptide conjugated protein microspheres. 
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performing M-mode imaging at one point on a tissue phantom. A 
step excitation or a sweep of frequencies applied to the sample 
under study is used to extract information about the mechanical and 
viscoelastic properties of the biological tissue. Doing this, one can 
find the resonant mechanical frequency of the biological sample as 
well.  
A standard OCT system can be readily modified to enable MM-
OCT imaging [79]. In the MM-OCT system, the magnetic field is 
applied using a solenoid, and imaging is performed on the sample 
immediately below the solenoid bore. Within the imaging volume 
of the sample, the radial components of the magnetic field are 
negligible and the magnetic field gradient is predominantly in the 
axial direction. The MNPs under the effect of magnetomotion due 
to an axial magnetic field result in a change in amplitude and phase 
of the interference pattern in a spectral domain OCT system. A 
sinusoidal magnetic field excitation with a frequency close to the 
mechanical resonance of the biological sample is used to perform 
MM-OCT imaging.  
Magnetomotive contrast has been demonstrated first with OCT 
by Oldenburg et al. [92] with a 3-D scaffold of macrophage cells 
loaded with iron oxide microparticles. The scatterers themselves do 
not exhibit significant optical scattering, but act as transducers, 
displacing the adjacent scatterers such as cells and organelles, and 
hence, can be detected using this contrast mechanism (Fig. 3b-d). 
Iron oxide MNPs have been topically administered to highly 
scattering media such as chicken skin (Fig. 4) and the sensitivity of 
this technique has been demonstrated in vitro [93]. This ability to 
track magnetically-labeled cells on micron-scales in scattering 
tissue scaffolds as well as in in vitro environments provides a new 
investigation tool to study the in vivo dynamics and subcellular 
transport phenomena. In vivo MM-OCT imaging of MNPs in the 
digestive tract of an African frog tadpole was demonstrated [79]. 
Rejection of physiological motion for in vivo imaging was 
accomplished by acquiring two successive axial scans with the 
magnetic field off and a third with the field on, and comparing the 
signal changes between the on and off scans (magnetomotion) with 
those between the two off scans (physiological motion). The main 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). (a) Magnetomotion principle. Representative images of macrophage cells in three-dimensional scaffolds are shown by (b) light microscopy and (c, d) 
structural OCT (red) and MM-OCT (green) signals. Control macrophages and macrophages allowed to uptake magnetite microparticles are shown in (c) and 
(d), respectively. Apparent cell sizes (approximately 8–30 m) are consistent with light microscopy observations. (c-d) images reproduced with permission 
from [92]. Copyright, Optical Society of America, 2005. (For interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this paper). 
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drawback of this study was the long imaging times needed to take 
three B-mode images for each measurement. This is not feasible for 
in vivo and real-time applications. Also, this method only tracked 
the amplitude of the OCT interference signal. 
The use of optical phase to obtain sub-wavelength displacement 
sensitivity is very powerful for imaging biological samples [94]. A 
differential-phase OCT system was proposed to detect (but not 
image) the magnetomotion of MNP-laden macrophages in an 
animal model [95]. A MM-OCT algorithm has been proposed that 
measures modulation in the optical phase due to magnetomotion 
and thereby deduce the sample displacement [96]. Magnetomotive 
signals from a specimen under study can be isolated with the help 
of two B-mode MM-OCT images, one image with the field off and 
one with the modulating field on. We can couple the mechanical 
excitation with the B-mode OCT scanning by modulating the 
magnetic field several cycles during the time taken to mechanically 
scan the imaging beam. Transverse Fourier spectra of B-mode 
images with and without the magnetic field indicate the 
contribution from magnetomotion compared to the structural 
contribution (Fig. 5). This system is capable of detecting MNP 
concentrations as low as ~2 nM within the sample, and from the 
phase information obtained through interferometric detection, 
displacements of MNPs as low as a few tens of nanometers can be 
measured.  
The dynamic behavior and transport of magnetic nanoprobes in 
biological tissues for different concentrations and temperatures can 
be effectively tracked using the MM-OCT technique [97]. Ex vivo 
magnetomotive imaging of diffusing MNPs in several types of 
tissues has been demonstrated. Using this method, it is possible to 
quantitatively estimate the diffusion and transport of MNPs in 
tissues and viscoelastic materials (Fig. 6). The studies have shown 
that the transport of MNPs in tissues depends on the temperature 
and the elastic nature of the tissue or supporting media. These 
results show that the magnetomotive technique would aid in 
understanding the actual localization and accumulation of 
functionalized MNPs targeted to specific sites. In vivo imaging of 
dynamic functionalized iron oxide MNPs has been demonstrated 
using MM-OCT in a pre-clinical mammary tumor model [98]. 
These MNPs are antibody functionalized to target the human 
epidermal growth factor receptor 2 (HER2 neu) protein, which is 
overexpressed in about 30% of human invasive breast carcinomas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). MM-OCT in tissue. Images were acquired from in vitro chicken breast tissue. Structural and MM-OCT images were acquired in tandem, without and 
with the administration of iron-oxide nanoparticles. Figure reprinted with permission [93]. Copyright, SPIE, 2005. (For interpretation of the references to color 
in this figure legend, the reader is referred to the web version of this paper). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Representative transverse Fourier spectra with and without 
magnetic field modulation at 100 Hz for B-mode imaging of a tissue 
phantom with 100 μg/g of MNPs. Spectral amplitudes were averaged over 
all rows of the image. As indicated, the low frequency peak contains the 
usual structural OCT data, and a peak at 100 Hz is specific to 
magnetomotion. Other peaks are attributed to background noise (including 
60 Hz and its harmonics). Figure reproduced with permission from [96]. 
Copyright, Optical Society of America, 2008. 
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[72, 99]. Using targeted MNPs, in vivo MM-OCT images exhibit 
strong magnetomotive signals in mammary tumor, and no 
significant signals were measured from tumors of rats injected with 
nontargeted MNPs or saline (Fig. 7). This study has also 
demonstrated the feasibility of multimodal imaging using MNPs as 
dynamic contrast agents for in vivo tumor imaging using MM-OCT 
and MRI. These magnetic nanoprobes can also be incorporated into 
systems that require magnetic manipulation of nanoprobes, 
including magnetic field-guided drug delivery systems for cancer 
treatment. 
The MNPs that are embedded in tissues or elastic materials act 
as dynamic nanotransducers that can be actuated externally using a 
magnetic field to evaluate the viscoelastic properties of the medium 
in which they are dispersed. The scatterers undergo underdamped 
oscillations when the magnetic field is applied step-wise (Fig. 8) 
[100], allowing for the measurement of the natural frequencies of 
oscillation of the samples. The sample embedded with MNPs and 
modulated with a sweep of frequencies exhibit mechanical 
resonance modes [101], which are well described by a linear 
damped harmonic oscillator model. This resonant frequency is the 
natural frequency of oscillation of each particular type of tissue and 
varies strongly with the elastic modulus of the sample. Direct 
correlation has been observed between the elastic modulus of 
biological tissues and their experimentally-measured mechanical 
resonant frequencies [97]. Hence, this technique can be used to 
extract the mechanical vibration spectra and therefore the elastic 
properties of biological tissues. This new method of magnetomotive 
optical coherence elastography (MM-OCE) would also find 
applications in real-time non-destructive analysis of soft 
viscoelastic tissues and various polymers.  
In another interesting application, Kim et al. [102] have applied 
the principle of magnetomotion to optical Doppler tomography to 
enhance the contrast of flowing red blood cells. In a system of 
flowing SPIONs, the contrast due to the subsurface-scatterer flow, 
and hence the Doppler shifts, can be enhanced by activating 
mechanical motion in the nanoparticles. Magnetomotive optical 
Doppler tomography (MM-ODT) has been demonstrated on 
Doppler images of flowing SPIONs under the influence of an 
externally applied magnetic field gradient [103].  
Laser speckle imaging (LSI) is another imaging technique 
where magnetomotion may be exploited for achieving better image 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). (a) Results showing MM-OCT signal intensity corresponding to transport of MNPs in different tissue types as a function of time. (b) Time versus 
temperature plot for MNP transport through muscle tissue. The vertical axis denotes the time taken for obtaining a saturated MM-OCT signal and horizontal 
axis shows the temperature in ºC. Figures reproduced with permission from [97]. Copyright, IEEE Photonics Society, 2010. (For interpretation of the 
references to color in this figure legend, the reader is referred to the web version of this paper). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). In vivo MM-OCT imaging of anti HER2 antibody functionalized MNPs in a preclinical mammary tumor model. (a) MM-OCT and (b) OCT images 
from (I) targeted MNP-injected, (II) non-targeted MNP-injected, and (III) saline-injected rats. MM-OCT signal (green channel) is superposed on the OCT 
signal (red channel). Figure reproduced with permission from [98]. Copyright, National Academy of Sciences, 2010. (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of this paper). 
(a)
(b)
500 μm 
(I) (II) (III)
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contrast. This technique may be useful in wide-field imaging 
applications for the detection of suspicious malignancies in 
biological tissues and defects. In magnetomotive (MM-) LSI, a 
magnetic field modulation of SPIONs embedded in the sample 
specimen could change the speckle properties of the collected 
images. Speckle spatial frequency analysis [104] or speckle 
variance properties [105, 106] of interframe intensity variance of 
OCT structural images acquired consecutively in a time dependent 
manner could be analyzed for detecting the flow or motion of 
sample features on micron scales. These techniques would find 
applications in imaging the microvasculature and blood flow. Kim 
et al. [107] have shown that magnetic activation of SPIONs with an 
externally-applied, high-strength magnetic field gradient 
modulates the speckle flow index (SFI) values estimated from 
speckle contrast
 
analysis of collected images. Subsequently, the 
contrast in laser speckle images has been enhanced by the 
magnetomotion of the nanoparticles.  
3.3. Magnetomotive Ultrasound 
SPIONs can act as dynamic contrast agents in ultrasonography 
using external time varying magnetic fields. In magnetomotive 
ultrasound (MM-US) imaging, circulating MNPs are subjected to 
modulating magnetic fields and these modulations are detected as 
frequency shifts in Doppler ultrasound measurements [108, 109]. 
Detection of magnetomotive modulations in ex vivo liver tissue has 
been demonstrated through ultrasonography. Liver specimens were 
collected from rats pre-injected with MNPs. The MNPs 
accumulated in the macrophages in liver. Doppler ultrasound 
measurements could detect the frequency shifts corresponding to 
the micron-scale displacements of iron-laden macrophage cells 
under a time-varying magnetic field modulation. These results 
indicate the potential of MM-US for molecularly-sensitive imaging 
on a cellular scale using ultrasound.  
Magnetic nanoparticles also provide a new possibility to 
increase contrast by magnetomotive manipulation during 
photoacoustic imaging. A multi-functional imaging system 
integrating ultrasound and photoacoustic imaging with magnetic 
manipulation can take advantage of each single modality by 
providing anatomical images and molecular function with greater 
contrast. A new class of gold nanoshells with a superparamagnetic 
iron oxide core (SPIOAu nanoshells) has been shown to have 
desirable optical and magnetic properties, enabling multimodal 
imaging [110, 111]. These nanoparticles can be guided to a specific 
site using an external guiding magnetic field, thereby enhancing the 
efficacy of nanoshell-mediated photothermal therapy. With a 
significant absorbance in the NIR region of the electromagnetic 
spectrum, they would efficiently act as photothermal agents for 
therapy. They would also find applications as dynamic contrast 
agents for in vivo real-time MM-OCT and MRI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Scatterer response upon step-wise modulation of a magnetic field. (a) Two-dimensional (x-z) cross-sectional (B-mode) amplitude OCT image of a 
silicone sample containing MNPs and TiO2 optical scatterers. The dashed line indicates the location in sample where M-mode imaging is performed with MM-
OCE. (b) M-mode amplitude OCT image of a region of scatterers acquired while the magnetic field is applied step-wise. (c) Average time-dependent scatterer 
changes along one axial position, illustrating both the changes in phase (red) and changes in amplitude (blue) as the magnetic field is applied step-wise, 
relative to an idle state with zero magnetic field. Figure reproduced with permission from [100]. Copyright, Optical Society of America, 2009. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web version of this paper). 
(a) (b)
(c)
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3.4. Magnetic Hyperthermia 
Iron oxide magnetic nanoparticles have shown to act as ideal 
agents for hyperthermia effects where alternating electromagnetic 
fields can be used to heat the nanoparticles, thereby directing 
thermal damage to passively- or actively-targeted cells and tissues. 
In magnetic hyperthermia, the energy in the magnetic field is 
transformed to heat through different mechanisms like eddy current 
loss, hysteresis loss, and relaxation loss due to Neel relaxation and 
Brownian relaxation. Larger particles (size ~ >30 nm) are generally 
regarded as having multiple domains and the main mechanism of 
heat generation is through hysteresis losses, while smaller particles 
(single domain particles) generate heat by Neel–Brownian 
relaxations [112, 113]. The transition between the two mechanisms 
occurs between 5-12 nm for various materials and is also frequency 
dependent.  
Magnetic hyperthermia can potentially reduce the adverse side 
effects caused to normal tissue through traditional treatment 
methods like systemic chemotherapy and radiation therapy. Also, 
magnetic hyperthermia effects can make the tumor tissue more 
susceptible or sensitized to radiation and other therapies [114]. It 
has been shown that magnetic hyperthermia can raise the 
temperature of localized regions in the body to temperatures in the 
range of 42-55
o 
C [115-120] without any systemic effects. Magnetic 
nanoparticle suspensions that are biocompatible can be heated using 
alternating electromagnetic fields. The rise in temperature depends 
upon the size, shape, and magnetic properties (permeability, losses 
and saturation moment) of the material, and the amplitude and 
frequency of the applied magnetic field. The magnitude of the 
magnetic field to which a human body can be exposed, however, is 
limited. The product of applied field strength (H) and frequency (f) 
should be limited to 6 x 10
6
 Oe-Hz to prevent injury due to 
excessive direct tissue heating. Ferrofliuds that are suspensions of 
iron oxide nanoparticles are ideal for this type of applications for 
their high biocompatibility and low toxicities while having high 
specific absorption rates. Hilger et al. [121] have shown that 
magnetic hyperthermia can induce cell apoptosis in cancerous cells 
by heating in the range of 41-46 
o
C. Heating over 46 
o
C can also 
result in thermoablation, leading to necrotic death of cancerous 
tissue.  
It has also been found that the magnetic properties desirable for 
hyperthermia applications of iron oxide nanoparticles can be 
improved by substituting Fe with other metals like Mn, Co, Al, or 
Zn, and hence the amount of nanoparticles that may be needed for 
inducing hyperthermia could be lowered. A number of other 
nanoparticles have been reported as being capable of providing 
magnetomotive contrast in imaging and suitable for hyperthermia 
applications like gold nanostars with an iron oxide core. Gd-doped 
iron oxide nanoparticles were reported for use in tumor therapy via 
magnetic hyperthermia in in vivo mouse models [122].  
4. CONCLUSIONS AND FUTURE PERSPECTIVES 
Magnetomotive molecular probes are promising tools for the 
noninvasive in vivo visualization of pathological conditions at the 
sub-cellular and cellular level. These probes have also demonstrated 
their capabilities as therapeutic tools for targeted drug delivery and 
hyperthermia applications. Molecular specificity remains the key 
strength of this technology that attracts the use of various probes in 
virtually all imaging modalities. In addition, these probes can be 
flexibly engineered and fabricated. Being multimodal and 
multifunctional, they have been used in many of the current clinical 
imaging modalities such as MRI, ultrasound, x-ray computed 
tomography, and nuclear imaging (PET and SPECT).  
The evolution of these molecular imaging probes continues to 
advance, with high optimism among the research communities as a 
hot topic of research in the coming years. Early studies on the 
synthesis, bioconjugation, targeting to biomarkers, in vitro 
evaluations, and pre-clinical investigations using small animal 
models have been promising and successful. Recent research in this 
field has primarily been focused on the development of molecular 
imaging agents and tools. Future research investigations are now 
being directed at the translation of these technologies to clinical 
applications, having nanoparticle-based diagnostic imaging agents 
and modalities enter clinical trials. In parallel, there is continued 
research in chemistry and biology, seeking new targeting moieties. 
Research in probe pharmacokinetics and modelling together with 
experimental small-animal multimodal imaging systems are being 
utilized to understand their biodistribution and dynamics in 
biological systems. Given the prevalence and impact of cancer on 
our lives, cancer detection, imaging, and therapy are expected to be 
the earliest applications for these magnetomotive molecular-
specific probes. 
Optical molecular imaging to date has been successful in 
catering to the requirements of the biological research community 
by providing better resolution, specificity, and sensitivity. Optical 
coherence imaging and microscopy are likely to play a significant 
role in the detection, diagnosis and evaluation of various cancers, 
offering real-time tracking and visualization across a range of size 
scales. New advances in catheter- and endoscope-based OCT 
technologies allow for the use of magnetomotive probes at internal 
sites accessed via minimally-invasive procedures. With the 
development of catheters and multimodal imaging tools, 
magnetomotive OCT has a strong potential to translate to the clinic. 
These same probes can also find utility in image-guided procedures, 
contributing to their multimodal multifunctional use. With recent 
demonstrations of magnetomotive ultrasonography, magnetomotive 
molecular probes are being explored by other imaging modalities in 
research like fluorescence and multiphoton imaging, photoacoustic 
tomography, MRI, and CT, enabling a potential translation to the 
clinic as multimodal imaging tools and the next generation of 
therapeutic strategies. Magnetomotive molecular probe-based 
multimodal imaging is likely to play a unique role in future clinical 
imaging and treatment practices.  
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